TopoTarget is a dynamic international biotech company dedicated to finding "Answers for cancer".

Founded by clinicians with a thorough knowledge of the molecular mechanisms of cancer, our goal is to find and develop cancer therapies, bringing them to the market to benefit patients. As well as a strong clinical development team, we have top class experts in our preclinical and regulatory departments. 

We currently have a broad pipeline which includes 9 products in clinical development. Using our own highly specialised dedicated sales team, we launched our first product, Savene® in Europe in 2006, and in the US in 2007 under the brand name Totect®.

Savene®/Totect® is used for the treatment of anthracycline extravasation, an accident that can occur during chemotherapy. TopoTarget is headquartered in Denmark and is listed on the OMX Nordic Exchange in Copenhagen under the symbol (OMX: TOPO).

The Company's strategy is focused on -

• Development of specialty oncology products to be marketed by its own  sales force in Europe and by partners elsewhere.

• Development of product candidates with potential broad cancer applications to be marketed by partners.